Trial Profile
Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2017
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
- Acronyms The stop-GIST trial
- 24 Jun 2017 New trial record